Although rare, secondary cold agglutinin disease (CAD), a type of autoimmune hemolytic anemia ... and significant hypocomplementemia (C3, 55.5; C4 <2.9). Despite corticosteroids and azathioprine, she ...

2 Blood film microscopic view of cold agglutinin disease (CAD), autoimmune hemolytic anemia diagnosis at medical laboratory. Causes of monoclonal, secondary CAD are Waldenström macroglobulinemia, ...

Decrease of C3 (56 mg/dL, normal range 80–170 mg/dL ... A blood smear revealed marked erythrocyte agglutination at room temperature (figure 1). The diagnosis of cold agglutinin disease (CAD) was ...

A rare case of diffuse large B-cell lymphoma (DLBCL) accompanied by cold agglutinin disease (CAD) has been documented. This case report was published in the Journal of Medical Case Reports.

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

The severity of the disease ... titre, C3 of 39.5 mg/dL (reference range 82 to 185 mg/dL), C4 of 2.9 mg/dL (reference range 15 to 53 mg/dL), double stranded DNA of 71 IU/mL and anti-Smith Ig >8.0 AI.

LAS VEGAS , NV, UNITED STATES, January 27, 2025 /EINPresswire / -- DelveInsight's“Cold Agglutinin disease Market Insight, Epidemiology And Market Forecast - 2034′′ report offers an in-depth ...

Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 ...